Caribou Biosciences’s New CRISPR Patent Isn’t About Gene Editing

If you ask people who don’t follow biotech too closely what they know about CRISPR, you might get two answers: genetic editing and a big patent fight.

But a new CRISPR patent highlights a lower-profile potential use for the biotechnology: genetic detection and analysis.

The U.S. Patent and Trademark Office granted the patent Tuesday to Caribou Biosciences, the Berkeley, CA-based company cofounded by Jennifer Doudna, a University of California, Berkeley, one of the scientists whose work has been crucial in turning a bacterial defense system into one of this century’s most promising and contentious developments.

Back to news